Evaluates human liver microsomes and S9 fraction as in vitro metabolism models for predicting the pharmacokinetics of small peptide doping agents including TB-500 (the actin-binding TB4 fragment), growth hormone-releasing peptides, and other short peptides. TB-500 was metabolized in liver-derived fractions in a pattern relevant to its in vivo behavior. Provides validated in vitro metabolism models for anti-doping laboratory research—establishing hepatic metabolic profiling as a practical screening tool for predicting doping peptide half-lives and metabolite profiles without requiring human studies.
Esposito, Simone; Deventer, Koen; Geldof, Lore; Van Eenoo, Peter